Feasibility of Combined Genomics/Transcriptomics for Patients With Lymphoma

Feasibility of Combined Genomics/Transcriptomics for Patients With Lymphoma

To learn more about the usefulness of molecular testing with the Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care.

Primary Objective:

• To determine the feasibility and turnaround of clinical WES and transcriptome sequencing

Secondary Objectives:

• To determine the frequency of actionable DNA and RNA alterations
• To determine the concordance of DNA and RNA alterations
• To determine the frequency of molecularly matched therapy
• To determine the feasibility of identifying mechanism(s) of acquired resistance with genomic profiling
• To determine the feasibility of molecularly matched therapy to acquired resistance alterations

Exploratory Objectives:

• To determine the feasibility of prioritizing targets with precision analytics
• To determine clinical outcomes in patients receiving molecularly matched therapy
• To determine the role of additional emerging diagnostic technologies

Patient Eligibility:

Inclusion Criteria:

1. Male/female patients who are at least 18 years of age on the day of informed consent signing.
2. Patients must have a histologically documented diffuse large B-cell lymphoma requiring therapy.
3. Provision of written informed consent for the study.

Exclusion Criteria:

1. None